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TESTICULAR CARCINOMAS

Incidence
Testicular neoplasms are relatively rare with approximately two new cases per 100,000 male population occurring per year. The peak occurrence is
between the ages of 20 .and 40. Because of their
highly malignant characteristics testicular neoplasms
must be treated aggressively if cure is to be achieved.
Etiology
The most significant etiologic factor is the predisposition for the occurrence of carcinoma in the
cryptorchid or undescended testicle. The cryptorchid
testis is at 40 to 50 times the risk of the normal scrotal
testicle for developing a cancer; various theories for
this predisposition to malignancy have been proposed. The most likely is that the cryptorchid testicle
is inherently abnormal (a very strong argument also
to explain its failure to descend) and therefore provides a fertile ground for neoplastic change.
Histology
Testicular tumors may be divided into neoplasms of germ cell origin (arising from the spermatogonia within the seminiferous tubules) and of nongerm cell origin (arising from the supporting Leydig
and Sertoli cells). The latter constitute only 5% of all
testicular tumors.
For purposes of histology and treatment regimens the germ cell tumors are divided into the semiCorrespondence and reprint requests to Dr. Pa ul F. Schellhammer, Hague Medical Center, Suite 100, 400 West Brambleton
Avenue, Norfolk, VA 23510.
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nomatous tumors which are most common, constituting approximately 60% of all testicular tumors,
and the non-seminomatous tumors constituting the
remaining 35% of tumors. The non-seminomatous
tumors consist of embryonal carcinoma, teratocarcinoma, teratoma, or choriocarcinoma. Rarely do each
of these types exist in absolutely pure form; most
nonseminomatous tumors combine the elements of
embryonal and teratomatous carcinomas and these
may have elements of choriocarcinoma as well. With
the exception of pure choriocarcinoma, a distinctly
rare entity comprising less than 1% of tumors, the
treatment regimen for the nonseminomatous tumors
is identical to and independent of the percentage of
each histologic type that constitutes the mixed tumor.
Diagnosis:
All testicular masses must arouse suspicion of
carcinoma and some swellings such as testicular hematomas, orchitis, and epididymitis may cause induration difficult to distinguish from a tumor diagnosed only by inguinal exploration and biopsy.
Treatment
When a testicular mass is suspect of carcinoma,
it must be explored through an inguinal incision. A
rubbershod or umbilical tape is used to obstruct the
venous return and therefore reduce or eliminate embolic dissemination during manipulation of the testicle. If there is some doubt about the diagnosis, the
testicle is isolated with towels, and a biopsy and a
frozen section are performed prior to orchiectomy
and removal of the cord. The testicle must never be
biopsied through the scrotum, either by incision or by
needle aspiration; by doing so an entirely new nodal
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chain for metastases is established. The testicle drains
to the para-aortic nodes, the scrotum to the inguinal
nodes. If the tumor cells seed in the scrotal incision,
which can easily occur, then the entire inguinal chain
is at risk for embolic metastases.
The diagnosis of testes tumors is too often delayed for a number of reasons. Routine and careful
bi manual examination of the testes is often omitted in
routine examinations. Furthermore, patients who
note testicular masses are often reticent to present
their complaints to a physician because of embarrassment, or fear of association with venereal disease.
Metastatic evaluation. Once a diagnosis is made
a number of radiologic studies, serum studies, and
urine studies are warranted to stage the neoplasm and
identify areas of metastases. The chest represents a
common area of distant metastases and should be
evaluated not only by anteroposterior and lateral xray, but by pulmonary tomograms . Lesions are frequently bilateral and multiple. The primary route of
drainage of the testicular lymphatics is to the paraaortic and paracaval nodes between the superior mesenteric and the inferior mesenteric arteries. Crossover drainage does occur and is most frequent from
the right side to the left. Bipedal lymphangiography is
of importance in identifying spread to the retroperitoneal nodes . Para-aortic a nd paracaval nodes
are well visualized as is, frequently, the supraclavicular node. Intravenous pyelogram also assesses the
retroperitoneum by evaluation of renal and/ or
ureteral deviation , compression, and deformity.
Computerized axial tomography (CT) scanning and
ultrasound studies can be used to delineate retroperitoneal masses precisely and may be used as
noninvasive techniques to follow these masses periodically during the course of chemotherapy or radiotherapy to evaluate treatment.
Staging of testes tumors is as follows:
Stage A: Tumor limited to testes, that is, no metastases .
Stage B: Tumor present in testes with metastases
limited to regional nodes, that is, paraaortic nodes below diaphragm.
Stage C: Tumor present in testes with metastases
beyond regional nodes, that is, metastases to scalene node, lung, bone, liver,
and so forth .
Seminomatous tumors. These neoplasms are
characteristically very radiosensitive. Radiothera py
constitutes the main method of treatment and rarely,
if ever, is surgery indicated. If the tumor is Stage A

(negative lymphangiogram and pulmonary tomograms ), radiation is given in the dose of 2,500 R to
the ipsilateral-iliac nodes and to the para-aortic
nodes bilaterally to the level of the diaphragm.
If the tumor is Stage B (evidence of nodal involvement on lymphangiogram), the fields are extended so as to include the mediastinum and bqth
supraclavicular areas, and the infradiaphragmatic
area is treated to 3,000 R. The 5-year survival rate for
patients with Stage A tumors, so treated, ranges
around 95%. If the tumor is Stage B (evidence of
positive para-aortic nodes), the 5-year survival rate
will range around 80%.
If the tumor is Stage C (evidence of pulmonary
visceral or osseous metastases), radiation therapy
may be given to these areas of metastatic involvement
if they are relati vely isolated, that is, one or two
pulmonary nodules in one lung lobe. If disease is
more diffuse, however, a radiomimetic chemotherapeutic agent, either chlorambucil (Leukeran) or cyclophosphamide (Cytoxan) is used . Five-year survival rates for Stage C tumors range between 40% and
50%.
The only indication for surgery for seminomatous tumors arises with the failure of what has
been diagnosed as seminoma to respond satisfactorily
to radiotherapy. In such a case one must suspect the
presence of non-seminomatous elements, and surgery
with excisional biopsy will eliminate the lesion, confirm a change in histology, and dictate a change in
treatment to that used for non-seminomatous neoplasms.
Non-seminomatous tumors. There is significant
controversy as to th e optimal management of nonseminomatous tumors with North American urologic
centers applying surgery, and European centers employing radiation therapy as the primary modes of
treatment of the retroperitoneal area . Non-seminomatous tumors are much more difficult to control with radiation than the seminoma and therefore radiation failures are more common .
In the United States a non-seminomatous neoplasm is approached as follows: if the tumor is Stage
A, a retroperitoneal node dissection is undertaken; if
lymph node dissection reveals no evidence of histologic metastases to the nodes, no further treatment is
undertaken ; and if the nodes are positive, chemotherapy is administered as the tumor is pathologically Stage B.
If the tumor is Stage B, a node dissection is again
performed and chemotherapy instituted postopera-
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tively. If nodal dissection is incomplete or there is
tumor spillage, radiotherapy postoperatively to the
retroperitoneal area is recommended. Chemotherapy
is administered for two years after the last evidence of
clinical disease is noted.
If the tumor is Stage C, chemotherapy is instituted and if clinically measurable metastatic disease
regresses, a node dissection is then considered.
Five-year survival rates for Stage A, non-seminomatous tumors range from 85% to 90% (the pathologist is not always 100% accurate and may have
missed microfoci in the excised lymph nodes and/ or
metastases may have skipped the retroperitoneal
nodes and dissiminated distantly without nodal involvement). Five-year survival rates for Stage B disease are 60% to 70% and for Stage C, 25% to 30%.
Tumor markers. Until recently, 24-hour urinary
choriogonadotropin was measured in patients with
testicular tumor in an effort to identify those with
choriocarcinoma which as a functioning cell would
produce choriogonadotropins detectable in the urine.
The assay used is a biological one and has all the
inherent difficulties of bioassays.
A serum radioimmunoassay has been developed
to overcome this difficulty. It measures the B chain of
human choriogonadotropin (termed Beta sub unit)
and is very sensitive and specific. Any elevation in the
male is abnormal and indicates the presence of functioning tumor cells.
Alpha-fetoprotein is a protein produced by the
fetus, but its production ceases and levels fall to
nanogram marks soon after birth. Testis carcinoma
cells may revert to the metabolic machinery of the
fetal cell and produce alph a-fetoprotein, causing increased serum levels. Like the Beta sub unit, elevated
alpha-fetoprotein identifies the presence of active tumor.
Tumor markers are sensitive indicators of residual microfoci of disease long before any evidence of
clinical or radiologic disease may appear. Active chemotherapy must continue until tumor markers are
reduced to and remain within normal levels.
CARCINOMA OF THE PROSTATE

Incidence
The incidence of carcinoma of the prostate is
steadily increasing; at the present time it is the most
common genitourinary malignancy and the second
leading cause of death from cancer among males
in the United States. Its incidence of 60 new cases/
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100,000 population and 20 deaths/ 100,000 population per annum is exceeded only by carcinoma of
the lung. The incidence of carcinoma of the prostate increases with age, and autopsy studies have
revealed it in 50% to 80% of males who have survived
to age 80. Thus, we can anticipate that with greater
longevity the diagnosis of prostatic carcinoma will
be made more frequently and the problems of
treatment of a malignancy in an aged population
will be of increasing concern.

Etiology
No specific carcinogen has been identified as the
cause of prostate cancer. The most likely inciting
event at present is a change in the hormonal milieu
which occurs as a natural consequence of aging. The
nature of the change and the hormone fluctuations
involved are as yet unidentified.

Anatomy and Histology
The prostatic glandular elements can be divided
into two major sectors-the inner periurethral glands
and the peripheral tuboalveolar glands which are
connected by long ducts to the prostatic urethra. The
periurethral glands are those which most frequently
give rise to benign hypertrophy and the peripheral
tuboalveolar glands to adenocarcinoma of the prostate.

Natural History
Carcinoma of the prostate is a neoplasm with
varied growth characteristics and degrees of malignancy. The tumor may be rapidly metastatic and
cause death within one to two years or it may be
slowly growing, metastasizing only five to ten, or
even fifteen, years after discovery of the primary lesion ; another five or more years may pass before the
metastases become life-threatening. This variability
makes it difficult to assess the efficacy of therapy, and
makes it necessary to follow patients for ten to fifteen
years after initiating treatment in order to judge its
value. The reason for this is that, given a tumor with
a relatively slow-growing and benign course, one cannot state whether prolonged survival is based on the
treatment administered or the low biologic potential
of that tumor. Unfortunately, at the present time
there are few characteristics, other than the grade of
anaplasia, that can be measured to identify at the
time of diagnosis which tumors will follow a benign
course from those which will not.
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Diagnosis
While a high index of suspicion may be generated by induration felt on digital rectal examination,
carcinoma of the prostate must be ultimately diagnosed by histologic proof of malignancy. A number
of other causes for induration of the prostate include
prostatic calculi, granulomatous prostatitis, nodular
prostatic hypertrophy and, more rarely, tuberculous
granulomas. Once a suspicious area of in duration or
nodularity is identified a transperineal or transrectal
needle biopsy employing the Vim-Silverman needle is
used to obtain tissue for histologic examination.
Other warning signals in the elderly male of
prostatic cancer include the onset or recent exacerbation of low back pain, possibly a reflection of
osseous metastases; the presence of sciatic pain, possibly a reflection of sciatic nerve impingement by
massive retroperitoneal lymphadenopathy secondary
to metastases; and the rapid progression of bladder
outlet obstruction which can be identical to that seen
with benign prostatic hypertrophy (BPH).
Radiographic identification of carcinoma of the
prostate is facilitated by the characteristic radiodense
or osteoblastic lesions most frequently found in the
pelvic bones and the lumbosacral spine. These may
be identified on routine skeletal survey, but more
early identification is provided by the technetium 99
phosphorous bone scan which identifies metastases
prior to radiographic skeletal changes. (It has been
shown that more than 50% of the bone must be
destroyed or replaced by malignancy before a routine
skeletal survey becomes positive). Intravenous pyelography may demonstrate obstruction at the ureterovesical junction secondary to prostatic malignant
growth and, specifically, involvement of the seminal
vesicles. Also the ureters may be displaced by retroperitoneal metastatic adenopathy.
Biochemical or serum abnormalities occur with
prostatic carcinoma. Serum acid phosphatase represents- the most characteristic and distinct abnormality; in essence, it is a tumor marker. It can frequently
be used to identify the presence of metastatic disease,
and its levels may be followed as a means of monitoring treatment; however, it is not a specific test as
acid phosphatase may be elevated in a number of
other diseases such as pulmonary embolism, muscle
necrosis, Gaucher disease, and osteosarcoma, to
mention a few. It is also not a very sensitive marker as
diffuse metastases may be present in the face of a
normal acid phosphatase. The recent development of
a radioimmunoassay for measurement of prostatic

acid phosphatase offers significant advantages for tumor staging, and follow-up. The immune assay is
specific for the prostatic fraction of acid phosphatase
and is sensitive to extremely minor changes in serum
levels of the enzyme. Elevation of alkaline phosphatase is a reflection of bony destruction and repair.
Serum calcium may be elevated as a result of. extensive osseous metastases.
Treatment
Many methods of treatment are used either individually or in combination. Transurethral resection
of the prostate is used to relieve obstruction. This is
obviously palliative and relieves symptoms but does
nothing to stem or alter the growth of the neoplasm.
Radical prostatectomy, namely the total removal of
the prostate gland and the seminal vesicles, is performed with the intent to cure by removal of all
neoplasm. Curative radiation therapy delivered from
a linear accelerator or cobalt source is directed at the
prostate and often the pelvic lymph nodes as well.
Interstitial implantation of radioactive seeds is used
in an effort to deliver high local doses.
Treatment is based on the staging of the disease
at the time of presentation: Stage A-carcinoma entirely unsuspected on physical examination, or on
serum chemical or radiographic examination but
which is found incidentally on pathologic examination of the prostate excised for presumed BPH, that
is, in the transurethrally resected prostatic chips or
the prostate enucleated by an open technique. Stage
B-tumor confined to the prostate gland on physical
examination specifically without lateral or seminal
vesicle extension; Stage C-tumor locally confined to
the pelvis but demonstrating lateral extension and
seminal vesicle invasion; Stage D-metastases to
lymph nodes, bone, lung, and so forth.
Management of Stage A depends to a large extent on the patient's age, the grade of lesion, and the
extent of the involvement. When only microfoci of
well differentiated neoplasm are present, it is reasonable to pursue no further treatment. If the tumor is
more extensive or poorly differentiated, treatment is
as outlined for Stage B.
For Stage B, either radical excision of the prostate and seminal vesicles (radical prostatectomy) or
treatment with external beam radiotherapy or interstitial implantation of radioactive sources (1-125
seeds) may be employed. The a dvantages of radiotherapy are the inclusion of the periprostatic tissue
(and thereby hoped-for sterilization of microscopic
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extensions outside the prostate) and avoidance of the
side effects of surgery, namely universal impotence
and a I 0% to 20% incidence of incontinence.
The survival rates for Stage 8 carcinoma of the
prostate are approximately 75% at five years, 45 % to
50% at ten years, and 25% to 35% at fifteen years.
In Stage C carcinoma of the prostate, extension
beyond the confines of the prostate and seminal vesicles usually makes cure by radical prostatectomy
highly unlikely; therefore, radiation therapy , either
external beam or interstitial seeds, constitutes the
mainstay of treatment. Occasionally it is also necessary to relieve prostatic obstruction by transurethral
prostatectomy either before treatment or immediately afterwards. Five- and ten-year survival rates for
Stage Care approximately 45% and 30% respectively.
The philosophy for treatment of Stage D carcinoma of the prostate varies throughout the country .
It is our policy to await the appearance of symptoms
prior to the institution of therapy. Cure of Stage D
prostatic neoplasm has not been documented, and
therefore palliation of symptoms, and prolongation
of survival remain the primary objectives of treatment. Conditions warranting treatment include systemic symptoms such as weight Joss, fatigue, weakness , bone pain, ureteral obstruction, and bone
marrow replacement as evidenced by anemia.
Hormonal manipulation (estrogen or orchiectomy) is the mainstay of treatment for metastatic carcinoma of the prostate . Dramatic relief from
pain and regression of metastases, and at times complete disappearance of the primary prosta tic lesion,
follow the administration of hormones, or castration.
The administration of estrogens works via the negative feedback system whereby high-estrogen doses
suppress luteinizing hormone (LH) and follicle-stimulating hormone (FSH), both of which are pituitary
trophic hormones stimulating the testes to produce
testosterone . Orchiectomy removes the source of
androgen production. It is felt at the present time that
either one of these modes is equally effective and can
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be expected to produce regression in approximately
80% of patients with prostate carcinoma. There is no
documented advantage from using both methods,
that is, estrogen plus orchiectomy as opposed to either one or the other alone, nor unfortunately is a
second regression seen with any frequency by applying one of these modes when a relapse occurs after
the institution of the other.
Estrogens have certain distinct disadvantages; an
orally ingested pill is required daily , nausea can occur, as can gynecomastia and other secondary sex
changes. Of greater significance is data demonstrating an increased incidence of death from cardiovascular disease, n a mely fluid retention, pulmonary edema,
and congestive heart failure in patients receiving estrogen therapy. Orchiectomy, a simple surgical procedure that can be performed under local anesthesia,
avoids these secondary effects of estrogen treatment.
Other forms of hormonal ablation include adrenalectomy and hypophysectomy, but these are rarely
used and have not been consistently successful in
offering extended palliation.
Local radiation therapy to painful osseous lesions may significantly relieve discomfort. Radiation
is reserved for treatment of well-localized areas of
painful metastases.
Cytotoxic agents have just come under investigation in clinical trials and hold some promise for treatment of estrogen failures. Investigation of certain
cytotoxic agents linked to hormones (Estracyst =
estrogen + nitrogen mustard ; Leo = prednisone +
chlorambucil) suggests that cytotoxic agents may be
delivered within the prostatic cancer cell by steroid
carriers which attach to hormone receptors . Other
agents which depend on the acid phosphatase enzyme
for cleavage to the active form are also in developmental stages .
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